EANS-News: Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC´s Advisory Committee on Immunization Practices

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Vienna, June 25, 2009 (euro adhoc) - Intercell AG (VSE: ICLL) today announced
that the U.S. Centers for Disease Control and Prevention (CDC) Advisory
Committee on Immunization Practices (ACIP) voted to update its previous
recommendations and include IXIARO, a new Japanese Encephalitis (JE) vaccine for
travelers to countries in Asia where the disease is endemic, as well as
Americans living in such high-risk areas.

ACIP made significant changes to their previous Japanese Encephalitis
recommendations, last updated in 1993, noting that many more travelers are now
visiting areas where the disease is endemic. In addition to recognizing the
recent licensure of IXIARO, the committee´s expanded recommendations urged
clinicians to consider vaccinating travelers visiting endemic areas during the
transmission season, even those on short-term visits, if they plan to spend a
substantial amount of time outdoors. The panel also concluded that IXIARO, which
is derived from a well-established cell line and does not contain stabilizers or
preservatives, has a lower risk of vaccine-associated adverse events than older
Japanese Encephalitis vaccines.

IXIARO received marketing approval from the U.S. Food and Drug Administration on
March 30, 2009 on the basis of studies that showed the vaccine is highly
immunogenic after only two doses. IXIARO has been shown to stimulate a
long-lasting immune response and to be well tolerated. It is the only currently
manufactured Japanese Encephalitis vaccine available in the United States.
IXIARO was developed by Intercell AG; the rights to market and distribute the
vaccine to the private sector in the United States are held by Novartis
Vaccines.

"The consequences of contracting this disease can be devastating due to the high
morbidity and mortality associated with the disease, making IXIARO a crucial
preventive tool for those spending time in endemic areas. It is gratifying that
the ACIP committee of the CDC has chosen to broaden its recommendations and to
recognize the benefits of IXIARO," said Gerd Zettlmeissl, Chief Executive
Officer of Intercell. "This underscores our commitment to serving the needs of
the travelers´ and of the military market and developing vaccines to address
unmet needs."

The ACIP consists of 15 experts in fields associated with immunization who have
been selected by the Secretary of the U.S. Department of Health and Human
Services to provide advice and guidance on the control of vaccine-preventable
diseases. ACIP develops written recommendations for the routine administration
of vaccines to children and adults in the civilian population. The ACIP is the
only entity in the federal government that makes such recommendations.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
[email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print